Abstract: The importance of astrocytic L-lactate (LL) for normal functioning of neural circuits such as those regulating learning/memory, sleep/wake state, autonomic homeostasis, or emotional behaviour is being increasingly recognised. L-Lactate can act on neurones as a metabolic or redox substrate, but transmembrane receptor targets are also emerging. A comparative review of the hydroxy-carboxylic acid receptor (HCA1, formerly known as GPR81), Olfactory Receptor Family 51 Subfamily E Member 2 (OR51E2), and orphan receptor GPR4 highlights differences in their LL sensitivity, pharmacology, intracellular coupling, and localisation in the brain. In addition, a putative Gs-coupled receptor on noradrenergic neurones, LLRx, which we previously postulated, remains to be identified. Next-generation sequencing revealed several orphan receptors expressed in locus coeruleus neurones. Screening of a selection of these suggests additional LL-sensitive receptors: GPR180 which inhibits and GPR137 which activates intracellular cyclic AMP signalling in response to LL in a heterologous expression system. To further characterise binding of LL at LLRx, we carried out a structure–activity relationship study which demonstrates that carboxyl and 2-hydroxyl moieties of LL are essential for triggering D-lactate-sensitive noradrenaline release in locus coeruleus, and that the size of the LL binding pocket is limited towards the methyl group position. The evidence accumulating to date suggests that LL acts via multiple receptor targets to modulate distinct brain functions.

Keywords: L-lactate; hydroxy-carboxylic acid receptor; OR51E2; GPR4; GPR137; cAMP; locus coeruleus; noradrenaline; next generation sequencing; structure–activity relationship

1. Introduction

Astrocytes, the electrically nonexcitable “cousins” of neurones, are strategically placed at the interface between the periphery and neuronal networks of the central nervous system. Among other functions, they handle the import and distribution of glucose, the main energy substrate used by the brain, as well as its storage in the form of glycogen [1]. Glycolytic breakdown of glucose to pyruvate, and its subsequent conversion to L-lactate (LL), yields two units of ATP for intracellular energy transfer or, alternatively, for use as a transmitter. If glycolysis is followed by oxidative phosphorylation, nearly 20 times as much ATP can be produced. This, however, does not mean that almost all ATP in the
cell is delivered by mitochondria. In fact, since glycolysis is very fast compared to the mitochondrial oxidation of pyruvate, the contribution of glycolysis to the pool of ATP may be comparable to that originating from oxidative phosphorylation [2], especially during peaks of high metabolic demand. In spite of the obvious discrepancy in energy efficiency, the brain produces large amounts of LL, much of which, surprisingly, is drained into the peripheral circulation [3]. The energetic or functional advantages of this metabolic imbalance are still controversial.

Average physiological extracellular levels of LL reported for the brain are in the sub- to low mM range, but they respond dynamically to plasma LL concentrations, central availability of oxygen, neuronal network activity, or metabolic triggers and can approach ~10 mM under extreme conditions such as seizure or hypoxia [4,5]. In principle, the ability to glycolytically process glucose to LL is shared by astrocytes and neurones, but astrocytes are held to be the main source of LL in the brain, at least under physiological resting conditions where there is a steeper intra-to-extracellular LL gradient in astrocytes as compared to neurones [6]. Astrocytes are known to tolerate hypoxic conditions better than neurones and may more easily upregulate glycolytic activity to bridge periods of oxygen demand exceeding supply [7]. Indeed, they have been shown to switch to aerobic glycolysis while sparing the limited oxygen for neuronal oxidative phosphorylation [8]. According to the astrocyte-to-neuron-lactate-shuttle (ANLS) hypothesis, the astrocyte-derived LL may benefit neurones as an additional energy substrate to sustain periods of elevated activity [6,9,10].

Whether as a valuable energy substrate or a glycolytic waste product, LL has been reported to modulate brain activity and behaviour in various functional contexts [5]. LL was shown to be essential in certain learning and memory paradigms ([11,12]; reviewed in [13]). It is also important for regulating sleep/wake states at the level of the lateral hypothalamic area, as well as negatively correlating with sleep-associated slow wave activity in the cortex [14–16]. Moreover, recent evidence suggests that it acts as an antidepressant in an animal model of depression [17]. Since central cyclic AMP (cAMP) signalling was found to be reduced in depressed patients, this could potentially be explained by the ability of LL to increase cAMP responses in astrocytes and some neuronal phenotypes [18–20].

We have previously reported a mechanism that is consistent with, and may contribute to, LL’s overall role as a central activator and regulator of brain state. We found that optogenetically induced release of LL from astrocytes into the extracellular space triggers noradrenaline (NA) release from adjacent noradrenergic neurones [20]. When microinjected into the locus coeruleus (LC) area, LL desynchronised the electroencephalogram activity in the cerebral cortex, indicating that the noradrenergic network was excited [20].

It is becoming increasingly clear that LL utilises a wide variety of signaling mechanisms to influence physiological outputs. These include not only multiple intracellular targets but also effects on putative receptors located on the plasma membrane of the cells.

1.1. Targets and Mechanisms of L-Lactate Signalling in the Brain

Upon import into neurones, LL can be reduced to pyruvate, raising the NADH/NAD+ ratio and switching on NMDA receptor-dependent immediate early gene expression ([21]; Figure 1). This pathway has been suggested to underlie some of the effects of ANLS, for example, memory formation [13]. A distinct pathway that may allow LL to exert long-term effects is via binding to and stabilizing the protein NDRG3 which, in turn, activates kinase activity in favour of Raf-Extracellular signal-regulated kinase signalling to support the tissue response to prolonged hypoxia [22].

In terms of reversible short-term metabolic signalling by LL, ATP-sensitive potassium channels have been suggested as an intracellular target. Analogous to the scenario in pancreatic beta cells, inhibition of these channels by LL-derived ATP increased excitation of orexin neurones in the hypothalamus during arousal [14,23].

In some instances, however, the effects of LL are not consistent with an intracellular action but can only be explained by activation of membrane-associated receptors from the extracellular side. The first specific LL receptor to be characterised was the G-protein coupled receptor (GPR) GPR81, currently
known as hydroxy-carboxylic acid receptor 1 (HCA1). Over recent years, further LL membrane receptor candidates have been identified, and the list is likely to lengthen (Figure 1).

Figure 1. Summary of potential L-lactate (LL)-mediated signalling actions in neurones. L-lactate which is transported into the cell can be metabolised and/or influence gene expression, e.g., via NMDA receptor modulation or ERK pathway activation. Increased ATP production can inhibit K<sub>ATP</sub> channel activity and increase cell excitability. LL may also act via a range of surface G-protein coupled receptors to stimulate or inhibit cAMP-dependent signalling, such as NA release in noradrenergic neurones. Black arrows indicate stimulatory action, red lines illustrate inhibitory effect. AC—adenylate cyclase; ERK(P)—phosphorylation of extracellular signal–regulated kinases; GPR4— orphan G-protein-coupled receptor 4; HCA1—hydroxy-carboxylic acid receptor; LL-OR—LL-activated olfactory receptor; LLRx—LL receptor on noradrenergic neurones; [mit]—mitochondria; NA—noradrenaline; NMDAR—NMDA receptor.

1.2. Hydroxy-carboxylic acid receptor (HCA1)

HCA1 was the first G-protein-coupled receptor (GPCR) to be described that is activated selectively by LL and a few related monocarboxylates (Table 1). In adipocytes where HCA1 was discovered, this leads to inhibition of lipolysis under conditions of glucose abundance in the fed state [24,25]. It has been reported that HCA1 is also expressed at low levels in the brain, predominantly in neurones, in cerebellum, hippocampus, and neocortex [26]. We carried out RNA sequencing on samples of neurones dissociated from the LC of rats and were unable to confirm its expression in these cells (Table 2). HCA1 is a G<sub>i</sub>-protein-coupled receptor and its activation inhibits cAMP production (IC<sub>50</sub>) in vitro according to various sources is between 5–30 mM [25–27]. The stereoisomer of LL, D-lactate (DL), also a weak agonist at HCA1 (Table 1; [25]).

In spite of its low potency, site-directed mutagenesis and molecular modelling predicts that LL binds specifically as a typical GPCR ligand rather than an allosteric modulator [25]. Being a G<sub>i</sub>-coupled receptor, HCA1 should evoke inhibitory effects (hyperpolarisation of the membrane and inhibition of transmitter release), which is opposite to what we found in noradrenergic neurones ([20]; Figure 1). In cultured embryonic cortical neurones, LL inhibited Ca<sup>2+</sup> signalling in a pertussin toxin-sensitive manner with a half-maximal inhibitory concentration (IC<sub>50</sub>) of ~5 mM [28]. Since this effect was mimicked by the HCA1 agonist 3,5-dihydroxybenzoic acid (3,5-DHBA), it was indeed consistent with signalling via HCA1.
Table 1. Characteristics of the known L-lactate receptors.

<table>
<thead>
<tr>
<th>Receptor</th>
<th>LL Potency (Range)</th>
<th>Intracellular Signalling</th>
<th>Other Agonists</th>
<th>Antagonists</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCA1</td>
<td>5–30 mM</td>
<td>Gi, cAMP↓</td>
<td>3,5-DHBA; α-HBA; glycolate; γ-HBA</td>
<td>nd</td>
<td>[25,26]</td>
</tr>
<tr>
<td>OR51E2</td>
<td>~4 mM</td>
<td>Gs, cAMP↑</td>
<td>Acetate; propionate</td>
<td>nd</td>
<td>[29]</td>
</tr>
<tr>
<td>GPR4</td>
<td>1–10 mM</td>
<td>allosteric modulation?</td>
<td>H+</td>
<td>NE 52-QQ57</td>
<td>[30]</td>
</tr>
<tr>
<td>LLRx</td>
<td>0.5 mM</td>
<td>Gs, cAMP↑</td>
<td>MPA; aHIBA; HMBA; 2HPA; KA (see Figure 2)</td>
<td>D-lactate</td>
<td>[20]</td>
</tr>
</tbody>
</table>

3,5-DHBA (3,5-dihydroxybenzoic acid), α-HBA (α-hydroxybutyrate), γ-HBA (γ-hydroxybutyrate); aHIBA (α-hydroxyisobutyric acid), HMBA (2-hydroxy-3-methylbutyric acid), 2HPA ((S)-2-hydroxypentanoic acid, MPA ((S)-(−)-2-methoxy-propionic acid), nd—not determined, LL—L-lactate. LLRx—putative LL receptor on noradrenergic neurones, GPR4—orphan G-protein-coupled receptor 4; OR51E2—LL-sensitive olfactory receptor; HCA1—Hydroxy-carboxylic acid receptor; Gi—G<sub>i</sub>-protein activation; Gs—G<sub>s</sub>-protein activation; KA—kynurenic acid.

Table 2. Expression of known L-lactate receptors in locus coeruleus neurones and astrocytes as determined by RNA sequencing.

<table>
<thead>
<tr>
<th>Gene Product of Interest</th>
<th>LC (p29)</th>
<th>LC (p7)</th>
<th>LC Neurones</th>
<th>Astrocytes</th>
</tr>
</thead>
<tbody>
<tr>
<td>DbH</td>
<td>43.3</td>
<td>527.7</td>
<td>3556.2</td>
<td>2.5</td>
</tr>
<tr>
<td>α2A-AR</td>
<td>116.8</td>
<td>307.0</td>
<td>268.4</td>
<td>115.9</td>
</tr>
<tr>
<td>HCA1</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>OR51E2</td>
<td>7.6</td>
<td>21.3</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>GPR4</td>
<td>70.5</td>
<td>26.0</td>
<td>34.6</td>
<td>24.5</td>
</tr>
</tbody>
</table>

Dopamine-β-hydroxylase (DbH), shown for reference as a marker of noradrenergic neurones, is highly expressed in locus coeruleus (LC) tissue from 29- and 7-day-old rats, and in dissociated noradrenergic neurones (area A6) from organotypic brain cultures. Values for a canonical GPCR, α2A-adrenoceptor (α2A-AR), provide a reference for the expression levels of this class of proteins. In comparison, known L-lactate receptors are found at low to negligible levels and not specifically on LC neurones. Numbers represent average FKPM (fragments per kilobase of exon per million fragments mapped) from duplicates. GPR4—orphan G-protein-coupled receptor 4; OR51E2—LL-sensitive olfactory receptor; HCA1—Hydroxy-carboxylic acid receptor.

1.3. Olfactory L-Lactate Receptors

More recently, OR51E2, a further LL-activated GPCR, has been reported in the mouse. OR51E2 belongs to the family of olfactory receptors which invariably couple to a specific subset of G<sub>s</sub>-proteins, thereby increasing cAMP levels (Figure 1). The EC<sub>50</sub> for cAMP elevation in vitro by LL was determined as 4 mM (Table 1; [29]). As expected, the OR51E2 receptor is found in the rodent olfactory bulb but it is also ectopically expressed in brain and periphery, for example, in glomus cells in the carotid body where its role in activation of carotid sinus nerve activity by LL is currently debated [29,31,32]. Olfactory receptors that are LL-sensitive may be involved in the maladaptive drive associated with the progression of chronic heart failure, in a vicious circle that leads to further deterioration of ischemic conditions and lactate acidosis [33,34].

Ectopic localisation of this olfactory receptor also extends to autonomic ganglia and to the brain, predominantly brainstem areas [35,36]. Since we previously showed that G<sub>s</sub>-coupling was involved in LL-mediated stimulation of noradrenergic transmission [20], we checked our transcriptomic data and found OR51E2 expression in LC tissue, but were unable to confirm its expression in isolated LC neurones (Table 2). We suggest that, since expression levels are low and the receptor appears to be not specifically localised to noradrenergic neurones, it is unlikely to account for the central effects of LL we had described earlier.
Nevertheless, in a study to follow up olfactory perception of LL, we discovered that not only mice but also humans can detect the odour of LL. However, OR51E2 knockout mice were still able to smell it [37]. This points to the existence of one or more additional LL-sensitive olfactory receptors which, if also expressed in the brain, would be expected to contribute to cAMP-mediated LL signalling. At the same time, olfactory receptors are notorious for their broad spectrum of activating ligands and are expected to act cooperatively to identify specific odorants.

1.4. Orphan G-protein-coupled receptor 4 (GPR4)

Since LL is one of the main extracellular organic acids, we investigated whether a proton-sensitive Gs-protein-coupled receptor, GPR4, may mediate or be modulated by LL ([38]; Figure 1, Table 1). Our evidence suggested that GPR4 contributes to the compensatory ventilatory response to increased CO2 levels in hypercapnic conditions. However, we found that, under physiological blood and brain LL concentrations, GPR4 is partially inhibited by LL and its sensitivity to protons is reduced [30].

GPR4 is prominently expressed in the endothelium of blood vessels, in periphery as well as brain [30]. Localisation in certain neuronal phenotypes such as in retrotapezoid and raphe nuclei, rostral ventrolateral medulla, septum, and LC in the mature rodent brain has also been demonstrated [30,39]. We detected a low level of expression in the LC (Table 2). However, since LL appears as a negative, presumably allosteric, modulator of GPR4-mediated cAMP production, it cannot be responsible for the effects of LL we observed on noradrenergic neurones [20]. Considering the comparatively minor impact of GPR4 on cardiorespiratory regulation and its wide distribution in the brain, including the raphe nuclei and related areas, it may be modulating processes mediated by these areas, an issue which remains to be investigated [30]. In setting the cAMP tone and levels of neuronal excitability it might, for instance, be involved in regulation of anxiety and depression.

1.5. The L-Lactate Receptor Responsible for Central noradrenaline Release

The receptor that mediates the effect of LL-induced NA release (LLRx) in the brain has not been identified to date. Our previous findings defined several properties for LLRx-mediated NA release ([20]; Figure 1): LL activates LLRx from the extracellular side and does not require entry into the cell. LL has a higher potency, by ~10-fold or more, at LLRx as compared to other so far identified LL receptors and is activated around the physiologically relevant LL concentrations in the healthy brain (0.2–0.5 mM). This makes it suitable for picking up physiologically relevant dynamic changes. The activation of LLRx by LL is inhibited in the extracellular presence of its stereoisomer DL. LLRx is most likely a Gs-coupled receptor as the effect of its activation depended on adenylate cyclase [20]. Since none of the receptors discussed above fits these requirements, our hypothesis is that LL activates one of the orphan G-protein-coupled receptors present in the brain and expressed by noradrenergic neurones. In the current study, we tested an array of LL derivatives for their ability to mimic the LL effect on NA release in order to further characterise the structural requirements for agonists of LLRx. In addition to the primary aim of these experiments, i.e., to establish a structure–activity relationship (SAR) between the LL molecule and LLRx to aid molecular modelling, a second objective was to lay the basis for antagonist and superagonist development. In addition, we carried out next-generation sequencing of neurones in the LC and identified orphan GPCRs which are expressed. We tested a selection of these in heterologous expression systems for their ability to activate Gs-proteins in response to LL stimulation.

2. Materials and Methods

2.1. Chemicals

Analougues of LL in which carboxyl-, hydroxyl-, or methyl groups were modified were obtained from commercial sources: 2-hydroxy-2-propan-sulfonic acid from Alfa Aesar (Heysham, UK); (±)-3-hydroxy-2-methylbutyric acid, 1-hydroxycyclo-propane-carboxylic acid,
and (S)-tetrahydro-furoic acid from Acros Organics (Thermo Fisher Scientific, Waltham, MA, USA); and kynurenic acid from Abcam (Cambridge, UK). All other analogues and reagents were obtained from Sigma-Aldrich (Merck, Darmstadt, Germany), unless stated otherwise. l-Lactate and analogues, acetate, and pyruvate were diluted in ddH$_2$O, adjusted to pH 7.4, and used at a final concentration of 2 mM unless otherwise specified. To evaluate blocking by DL, DL was co-applied with LL or LL analogues at a final concentration of 200 µM.

2.2. Organotypic Brain Slice Preparation

All animal procedures were performed in accordance with the UK Animals (Scientific Procedures) Act, 1986, and covered by, PPL 30/3121.

Brainstem slice cultures were prepared as described previously [20]. In brief, 6–7-day-old Wistar rat pups were terminally anaesthetised and decapitated, and the brainstem was immediately removed. Slices of 200 µm thickness were cut at the level of the LC in ice-cold sterile dissection medium (in mM: kynurenic acid 1; Hepes 1; glucose 20; MgCl$_2$ 10) using a vibrating microtome (7000 smz, Campden Instruments, Loughborough, UK). Slices were plated onto cell culture inserts (Millicell PICMORG50, Millipore, Watford, UK) and supplied with 1 mL per well feeding medium (Opti-MEM; 51985-026, Thermo Fisher Scientific, Loughborough, UK) supplemented with 25% fetal bovine serum, 25 mM glucose, and 1% penicillin (10,000 units)/streptavidin (10 mL/L)). To visualise noradrenergic neurones in the LC, we added ~10$^9$ TU/mL of the adenoviral vector (AVV) AVV-PRSx8-EGFP, which results in green fluorescent protein (EGFP) expression under PRSx8 promoter control [40]. To enable visualisation of astrocytes, an AVV with transcriptionally enhanced glial fibrillary acidic protein (GFAP) promoter was used to express EGFP (AVV-sGFAP-EGFP; [41]). Slices were kept at 37 °C and in 5% CO$_2$ for 7–12 days prior to experiments to allow for AVV-mediated protein expression.

2.3. Fluorescence-Activated Cell Sorting and RNA Sequencing of Locus Coeruleus Neurones and Astrocytes

Organotypic brain slices including LC were transduced with AVV-PRSx8-EGFP or AVV-sGFAP-EGFP. The LC area was dissected, and cells were dissociated as described previously [42], with modifications. The tissue was first digested at 37 °C for 10 min in 5 ml of Hank’s Balanced Salt solution (HBS) in mM: 136 NaCl, 5.3 KCl, 4.1 NaHCO$_3$, 1.6 CaCl$_2$, 0.8 MgSO$_4$, 0.44 KH$_2$PO$_4$, 0.13 Na$_2$HPO$_4$, 10 HEPES, 5.5 D-glucose) containing 30 U of papain (Sigma-Aldrich / Merck, Darmstadt, Germany) under orbital shaking, before washing off the papain and triturating with a fire-polished Pasteur pipette. Cells were gently pelleted (3 min, 900 rpm), resuspended in HBS, and filtered through a 50 µm mesh. EGFP-positive cells were sorted using 488 nm laser excitation and 510–550 nm emission in a Becton Dickinson InFlux cell sorter (BD Biosciences, Franklin Lakes, NJ, USA) running BD Software version 1.2. Viable cells were identified based on light scatter and the exclusion of propidium iodide. In addition, single-cell gating was used to exclude doublets and aggregated cells. Following fluorescence-activated cell sorting (FACS), more than 100 cells were collected into 100 µL of 2% Triton in phosphate-buffered saline containing 1 µL RNAseOUT (Invitrogen, Thermo Fisher Scientific, Loughborough, UK), and stored at −80 °C until processed further.

Sequencing libraries for next-generation sequencing (NGS) were prepared with 250 ng of total RNA using Illumina’s Truseq RNA Sample Preparation Kit v2 (Illumina, Inc., San Diego, CA, USA) following the manufacturer’s protocol. Final PCR-enriched fragments were validated on a 2200 TapeStation (Agilent Technologies, Santa Clara, CA, USA) and quantitated via qPCR using Kapa’s Library Quantification Kit (Kapa Biosystems, Wilmington, MA, USA) on the QuantStudio 6 Flex Instrument (Thermo Fisher, Waltham, MA, USA). The final library was sequenced by 50 bp paired-end sequencing on a HiSeq 2500 (Illumina). Illumina BCL files were converted and demultiplexed (bcl2fastq 2.17). FASTQ files were trimmed of adapter sequences (CutAdapt 1.8.3) and aligned to mm5 (STAR 2.5). Aligned reads were summarised as gene-level counts (featureCounts 1.4.4) and as transcripts per million (Kallisto 0.43.0). Sequencing and quality control reports were generated (FastQC 0.11.4 and
Qualimap 2.1.3). Pairwise differential expression analysis was conducted with the R package DESeq2 (1.10.1)

2.4. Measurement of Noradrenaline Release

In our earlier study, we used fast scan cyclic voltammetry to detect NA release in organotypic slices of the LC in response to LL stimulation. Here, in order to expand selection of LL analogues tested and to increase throughput, we implemented an approach based on cell-based neurotransmitter fluorescent engineered reporter cells (CNiFERS; Supplementary Materials Figure S1) [43]. CNiFERS are derived from a HEK293 cell line that stably expresses the Ca\textsuperscript{2+} indicator TN-XXL and a human α1 adrenoreceptor. Binding of NA to the adrenoceptor activates G\textsubscript{q}-protein signalling, leading to an increase in cytosolic Ca\textsuperscript{2+} through the phospholipase C-inositol triphosphate pathway which is imaged through the FRET ratio of TN-XXL (Supplementary Materials Figure S1A,B). CNiFERS showed nanomolar sensitivity to NA (EC\textsubscript{50} = 31 ± 1.75 nM).

To monitor NA release from organotypic brain slices, 4 × 10\textsuperscript{5} CNiFERS were plated 24 h prior to experiments on a cell culture insert (Supplementary Materials Figure S1C). Imaging experiments were performed at 34 °C under continuous perfusion (150 mL/h) with HEPES-buffered solution (HBS, pH 7.4; in mM: NaCl 138; KCl 5.5; Na\textsubscript{2}HPO\textsubscript{4} 0.25; KH\textsubscript{2}PO\textsubscript{4} 0.5; CaCl\textsubscript{2} 1.67; MgSO\textsubscript{4} 0.8; NaHCO\textsubscript{3} 4.25; HEPES 10; Glucose 5.5) in a tissue chamber mounted on a Leica SP5 confocal microscope. Images were collected in a time-lapse mode (0.25 Hz) with excitation at 458 nm and dual emission set to 462–501 nm (Citrine) and 519–595 nm (ECFP). Fluorescence intensities of Citrine and ECFP channels were exported and analysed offline in Excel (Microsoft, Redmond, WA, USA). The FRET ratio (ECFP/Citrine) was calculated, plotted against time, and the area under the curve (AUC) following LL/analogue stimulation was determined as FRET ratio \( x \) s. CNiFER responses were calibrated against 100 nM NA to allow evaluation of total NA release in nM \( x \) s.

2.5. Patch Clamp of Noradrenergic Neurones

Cultured slices containing the LC and transduced with an AVV-PRSx8-eGFP were transferred to a recording chamber mounted on an upright SP-2 confocal microscope (Leica, Wetzlar, Germany) and continuously superfused with HEPES-buffered solution (in mM: NaCl 137, KCl 5.4, Na\textsubscript{2}HPO\textsubscript{4} 0.25, KH\textsubscript{2}PO\textsubscript{4} 0.44, CaCl\textsubscript{2} 1.3, MgSO\textsubscript{4} 1.0, NaHCO\textsubscript{3} 4.2, HEPES 10, Glucose 5.5; pH 7.4) at 34 ± 1 °C. Current-clamp whole-cell recordings were sampled at 10 kHz using an AxoClamp 2B amplifier (Molecular Devices, San Jose, CA, USA) and a 1401 interface with Spike 2 software (CED, Cambridge, UK). Recording pipettes were pulled with a vertical puller (Narishige PC-10) to 3–5 M\textOmega resistance and filled with pipette solution (in mM: potassium gluconate 130, HEPES 10, EGTA 5.5, NaCl 4, MgCl\textsubscript{2} 2, CaCl\textsubscript{2} 1, ATP 2, GTP 1, and glucose 5). After recording 5–10 min of stable baseline in current clamp, LL or its analogues were superfused with the chamber solution for 5–10 min.

2.6. GloSensor Assay of Intracellular cAMP Accumulation

Clones of a selection of human orphan GPCR open reading frames were commercially obtained: GPR61 and GPR176 from cDNA Resource Center (www.cdna.org); GPR81, GPR137, GPR137B, GPR158, GPR180 from SourceBioScience (www.sourcebioscience.com); GPR155 from Origene (www.origene.com); rodent GPR162 was synthesised by Eurofins Scientific (www.eurofins.co.uk). The open reading frames of the receptors were cloned into the expression plasmid pEGFP-N1 under control of the human cytomegalovirus promoter, upstream of a human internal ribosomal entry site, followed by the enhanced green fluorescent protein sequence.

The GloSensor assay was used for cAMP measurements as previously described, with modifications [42]. HEK293 cells were plated in 96-well white polystyrene plates (Greiner Bio-One, Kremsmünster, Austria) in DMEM media ( Gibco, Thermo Fisher Scientific, Loughborough, UK) supplemented with 10% fetal bovine serum and 1% penicillin (10,000 units)/streptavidin (10 mL/L)), at a density of 4 × 10\textsuperscript{5} cells/mL to achieve ~70% confluence for transfection. After 20 h, cells were
transiently co-transfected with the GloSensor cAMP plasmid GLO22F and a plasmid encoding the GPCR of interest using Trans-IT 293 (Mirus) according to the manufacturer’s protocol. Transfection efficiency was confirmed by fluorescent visualisation of EGFP. Twenty-six hours after the transfection, cells were incubated with 850 µM beetle luciferin potassium salt (Promega, Southampton, UK) at pH 7.4 for 2 h in the dark. Prior to adding drugs, media was changed to HBS (Gibco) buffered with 20 mM HEPES and titrated to the desired pH. Cells were incubated with LL for 20 min in a final well volume of 100 µL. Luminescence measurements of cAMP accumulation were obtained using an Infinite M200 PRO microplate reader (Tecan, Männedorf, Switzerland).

2.7. Statistical Analysis

Data are expressed as mean ± standard error of the mean (SEM). Groups were compared using Student’s t-test or one-way ANOVA as indicated. GraphPad Prism (version 7; La Jolla, CA, USA) was used for data processing and to calculate EC$_{50}$.

3. Results

3.1. L-Lactate Releases Noradrenaline from Locus Coeruleus Neurones

To detect LL-induced release of NA we used a cell-based reporter system developed in D. Kleinfeld’s laboratory [43]. These “α1 CNiFER” cells respond with a robust Ca$^{2+}$ increase to NA which is registered through a ratiometric Ca$^{2+}$ indicator which they express. Consistent with our previous observations using fast-scan cyclic voltammetry, a transient change in α1 CNiFER cell signals confirmed that LL (2 mM) evokes NA release from LC neurones in organotypic slices. As we previously reported, this effect was blocked by DL (200 µM) and was independent of the caloric value of LL since neither pyruvate nor acetate (2 mM) triggered NA release [20] (Supplementary Materials Figure S1D).

3.2. Structural Requirements for the Agonistic Action of L-Lactate on Noradrenaline Release

In order to characterise the structural features required for LL binding to LLRx, we chose commercially available LL analogues in which the carboxyl, hydroxyl, or methyl groups were modified (Figure 2A–D). In addition, the effect of chain extension by increasing the distance between the OH and the carboxylate group of LL (e.g., 4, Figure 2C) or replacing the methyl group of LL with longer alkyl (9, 10) or aralkyl chains (13–15, Figure 2D) was studied. Conformational restriction by carbocyclic (5) or heterocyclic ring (7, 11) formation was also investigated (Figure 2C,D). Each analogue was tested at 2 mM for its ability to evoke NA release, and the response was normalised to the effect of equimolar LL tested in the same slice (Figure 2E).

L-lactate analogues with modified carboxyl (1), hydroxyl (3), and methyl groups (8–10 and 15) and the heterocyclic analogues (7 and 11) stimulated NA release; however, none of these were significantly more efficacious than LL (Figure 2E). All other test compounds (2, 4–6, 12–14) evoked significantly smaller responses, leading to less than 50% of the NA release triggered by LL application (Figure 2E). We then further focused on the 8 active LL analogues to test for antagonistic properties of DL, and found that analogues (S)-(−)-2-methoxypropionic acid (3, MPA; Figure 2C), α-hydroxyisobutyric acid (8, aHIBA; Figure 2D), 2-hydroxy-3-methylbutyric acid (9, HMBA; Figure 2D), (S)-2-hydroxyl-pentanoic acid (10, 2HPA; Figure 2D), and kynurenic acid (11, KA; Figure 2D) fulfilled the criteria for mimicking the effect of LL on NA release (Figure 2F; [20]).

We have previously shown that the effect of LL on NA release was paralleled by depolarisation of noradrenergic neurones, increasing their excitability [20]. In the current set of experiments, we extended this dataset and compared resting membrane depolarisation caused by LL with the effect of LL analogues (Table 3; Supplementary Materials Figure S2). l-lactate, aHIBA (8, Figure 2D), and HMBA (9, Figure 2D) caused depolarisation in a significant proportion of neurones. However, MPA (3, Figure 2C), 2HPA (10, Figure 2C), and KA (11, Figure 2C), also powerful NA-releasing LL mimetics,
evoked no depolarisation (Tables 1 and 3), suggesting that in noradrenergic neurones, depolarisation and cAMP-dependent transmitter release evoked by LL are not coupled in an obligatory way.

Figure 2. The structure–activity relationship (SAR) between L-lactate analogues and noradrenaline release in locus coeruleus characterises L-lactate binding properties at LLRx. (A) Moieties of the L-lactic (LL) acid molecule. The selection of tested LL analogues had alterations in the carboxyl group (B) (yellow highlight), in the hydroxyl group (C) (red highlight); and in the methyl group (D) (blue highlight). (E) LL analogues 1, 3, 7, 8–11, and 15 (2 mM) triggered more than 50% response in noradrenaline-sensitive α1 CNiFER cells as compared to 2 mM LL (100%). The rest of the tested analogues evoked significantly smaller responses compared to LL (**p < 0.01, *p < 0.05 vs 2 mM LL application for each analogue, paired t-test). (F) The effect of analogues 3 and 8–11 was blocked by pre-incubation with 200 µM D-lactate (DL; #p < 0.05 vs the same analogue without DL, paired t-test; E/F—data represented as mean ± SEM).
Table 3. Depolarisation of locus coeruleus neurones evoked by L-lactate and its analogues that cause D-lactate-sensitive noradrenaline release.

<table>
<thead>
<tr>
<th>LL Analogue (Figure 2)</th>
<th>Cells Analysed (number)</th>
<th>Cells Depolarised (%)</th>
<th>Vm (mV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LL</td>
<td>94</td>
<td>34</td>
<td>7.3 ± 1.1</td>
</tr>
<tr>
<td>3</td>
<td>8</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>28</td>
<td>43</td>
<td>6.2 ± 1.3</td>
</tr>
<tr>
<td>9</td>
<td>9</td>
<td>67</td>
<td>5.3 ± 1.0</td>
</tr>
<tr>
<td>10</td>
<td>8</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>7</td>
<td>14</td>
<td></td>
</tr>
</tbody>
</table>

L-lactate (LL) analogue numbers as displayed in Figure 2. Resting membrane potential data (Vm) are displayed as mean ± SEM in cells that showed a response.

3.3. Orphan GPCRs as Putative Targets of L-Lactate

We used the DiscoveRx panel of orphan GPCRs (orphanMAX, LeadHunter; Fremont, CA, USA) to screen for the activity of LL (2–8 mM) and filtered the results for those orphans that were expressed in the LC, based on our NGS data (Table 4).

Only one of the orphan receptors on the panel, GPR162, satisfied the DiscoveRx criteria of >30% for significant activation by LL (at 8 mM). The response of several other receptors, however, exceeded 3 times the standard deviation of the baseline. Note that HCA1 (GPR81) did not respond to the maximum concentration of 8 mM LL as employed in our DiscoveRx screen, indicating that this assay might not be suitable for detection of signalling through these low-affinity receptors.

We considered those orphan GPCRs with likely Gs-protein or unknown coupling that were expressed in noradrenergic neurones of the LC, but not in astrocytes, for further testing (Table 4). Receptors were transiently expressed in HEK293 cells and subjected to the GloSensor cAMP assay to test for the response to LL (Table 4; Figure 3). As expected, HEK293 cells transiently transfected with GPR81 showed a concentration-dependent reduction in cAMP accumulation when stimulated with LL (Figure 3A). Another orphan receptor, GPR180, responded with decrease in cAMP to both 1 mM and 10 mM LL (Figure 3B). The only orphan receptor to significantly increase cAMP production with LL in the range of 1–5 mM was GPR137 (Figure 4A,C). In contrast, its paralogue, GPR137B, which is also highly expressed in noradrenergic cells of the LC, did not respond to 2 mM LL (Figure 4B).

The enantiomer of LL, DL (0.4 mM), did not activate GPR137 to increase cAMP production (Figure 4C). Co-application of 0.4 mM DL with 2 mM LL, which in our previous study blocked LL-evoked effects on NA release, did not significantly affect cAMP accumulation in comparison to 2 mM LL application alone (Figure 4C).

Table 4. Screening of heterologously expressed orphan GPCRs for activation by L-lactate.

<table>
<thead>
<tr>
<th>GPCR</th>
<th>Coupling?</th>
<th>Activation (%) by LL (mM)</th>
<th>Expression in LC (NGS)</th>
<th>cAMP Assay: Activation by LL (0.5–10 mM)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2</td>
<td>4</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>GPR61</td>
<td>Ga</td>
<td>−2% 16% 19%</td>
<td>97 183 163 0</td>
<td>No response</td>
</tr>
<tr>
<td>GPR81</td>
<td>Gi</td>
<td>1% 3% 3%</td>
<td>0 0 0 0</td>
<td>Decrease</td>
</tr>
<tr>
<td>GPR137</td>
<td>Gs?</td>
<td>6% 4% 3%</td>
<td>959 628 196 577</td>
<td>Increase</td>
</tr>
<tr>
<td>GPR137B</td>
<td>?</td>
<td>nd</td>
<td>226 83 140 125</td>
<td>No response</td>
</tr>
<tr>
<td>GPR146</td>
<td>?</td>
<td>−3% 10% 20%</td>
<td>129 49 6 312</td>
<td>nd</td>
</tr>
<tr>
<td>GPR155</td>
<td>RGS?</td>
<td>nd nd nd</td>
<td>842 412 140 36</td>
<td>No response</td>
</tr>
<tr>
<td>GPR158</td>
<td>RGS7?</td>
<td>nd nd nd</td>
<td>1692 433 613 1</td>
<td>No response</td>
</tr>
<tr>
<td>GPR162</td>
<td>?</td>
<td>−9% 15% 30%</td>
<td>1293 1012 282 64</td>
<td>No response</td>
</tr>
<tr>
<td>GPR176</td>
<td>Gz</td>
<td>−8% 2% 9%</td>
<td>193 196 190 9</td>
<td>No response</td>
</tr>
<tr>
<td>GPR180</td>
<td>Gi?</td>
<td>nd nd nd</td>
<td>768 542 520 83</td>
<td>Decrease</td>
</tr>
</tbody>
</table>

The combination of DiscoveRx panel readout and GloSensor assay for cAMP production suggests further L-lactate (LL)–sensing GPCR candidates. Apart from GPR81, this selection of receptors is expressed in locus coeruleus (LC) neurones at medium to high levels. Coupling information obtained from www.genecards.org. NGS–RNA-Seq by next-generation sequencing; nd—not determined.
we hypothesised that LLRx is most likely a GPCR that activates G7 but hydrogen bond donation is not necessary to trigger NA release. THFA (it may be that HPSA is decomposing into acetone and sulphuric acid, leading to a false positive result.

group in HPSA (1, Figure 2B) did result in triggering NA release, but eliminated the antagonist effect

4. Discussion

This study aimed to further characterise LLRx, the LL receptor which mediates the communication between activated astrocytes and noradrenergic neurones [20]. Our previous evidence had suggested that LL acts at an extracellular site and was not consistent with the modulation of KATP channels. Based on the sensitivity of the effect to inhibition of adenylate cyclase or protein kinase A, we hypothesised that LLRx is most likely a GPCR that activates Gα-protein signalling, suggestive of an orphan GPCR or one of the olfactory receptors.

The potency of LL via its action on LLRx (EC50 ~0.5 mM) should be low compared to that of other endogenous GPCR ligands. For example, NA acting at β-adrenoceptors is around three orders of magnitude more potent (see Supplement in [44]). It is, however, fully consistent with a specific response based on low-affinity binding, given the high physiological extracellular LL concentration in the brain. Indeed, in comparison to the other LL receptors reported to date, HCA1 and OR51E2, the EC50 of LL at LLRx is around 10-fold lower and appears well correlated with the operational range of brain LL concentrations. It is, therefore, most suitable for mediating a dynamic physiological response to LL.

The experimental disadvantage of a low-affinity ligand–receptor interaction is that it rules out specific pull-down approaches to concentrate and biochemically analyse the receptor. Hence, we adopted an alternative approach to evaluate the properties of the LL–LLRx interaction and to determine an agonist profile for the LLRx-mediated stimulation of NA release.

The carboxyl group seems to be essential for LL’s agonist activity as it was intact in all NA-releasing analogues, and methylation of the carboxyl group to form the ester analogue M-LL abolished the effect (2, Figure 2B,E,F). Replacement of the carboxyl group by a more acidic sulfonate group in HPSA (1, Figure 2B) did result in triggering NA release, but eliminated the antagonist effect of DL. This suggests that HPSA acts via a different mechanism than by activation of LLRx. Indeed, it may be that HPSA is decomposing into acetone and sulphuric acid, leading to a false positive result.

The 2-hydroxyl group was intact in most of the active LL analogues, indicating its importance for NA release. Most analogues with 2-OH deletion or modifications, particularly addition of large groups, were inactive, apart from MPA, THFA, and KA (3, 7 Figure 2C, 11, Figure 2D, respectively). The DL-sensitive effect of MPA indicates that the hydroxyl group may act as a hydrogen bond acceptor, but hydrogen bond donation is not necessary to trigger NA release. THFA (7, Figure 2C) can be thought of as a conformationally restricted analogue of LL and MPA (3, Figure 2C), while HCPA...
(5, Figure 2C) is a conformationally restricted analogue of LL and aHIBA (8, Figure 2D). THFA and HCPCA were less active than the parent molecules MPA and aHIBA, respectively, suggesting that the conformations of THFA and HCPCA are not optimal for interaction with LLRx. Kynurenic acid (KA, 11, Figure 2D) can be thought of as a conformationally restricted analogue of LL in which the NH group acts as a mimic of the OH group of LL and the methyl group of LL is incorporated into the ring structure. The 4-oxo group of KA, which is a hydrogen bond acceptor, may also play a role in interacting with LLRx. Future SAR studies are needed to explore this possibility.

Addition of a second methyl group in the α-position, as in aHIBA (8, Figure 2D), or extension of the carbon chain from the methyl group as in HMBA and 2HPA (9, 10, Figure 2D), supports activation of LLRx. However, large lipophilic residues replacing or added as substituents to the methyl group prevent DL-sensitive NA release (12–15, Figure 2D), indicating a limitation of size in the binding pocket.

The comparison of the analogues that cause NA release and those that evoke membrane depolarisation shows that, in noradrenergic neurones, NA release can be evoked without necessarily increasing the cells’ electrical excitability. This is unsurprising, given previous evidence for cAMP-mediated increase in exocytosis [45]. In fact, extensive evidence indicates that depolarisation should not be the primary mechanism regulating NA release, because noradrenergic neurones are characteristically depolarised at rest. Membrane potentials of LC neurones, in vitro as well as in vivo, are typically near −50 mV (Supplementary Materials Figure S2; [20,46–48]). Moreover, LC neurones in vivo and in slices tend to generate a constant low-frequency stream of action potentials while their excitation by a sensory stimulus triggers only a very short (~20 ms) barrage of 3–5 additional action potentials which is followed by a long period of quiescence lasting hundreds of milliseconds [49,50]. Therefore, the conventional logic of neuronal networks where high-frequency action potential activity triggers release of a neurotransmitter, such as glutamate, does not apply to noradrenergic neurones. A mechanism which sensitises the NA release machinery and potentiates NA release to the steady-state level of intracellular Ca^{2+} (with or without additional depolarisation) should be a much more effective way to control NA release.

It is also important to note that the chemicals tested here can affect multiple targets. Kynurenic acid, for example, while effectively triggering DL-sensitive NA release, is also a well-known glutamate receptor antagonist [51]. Blocking of glutamate receptors theoretically should lead to a decrease rather than an increase in neuronal excitability, but KA nevertheless triggered release of NA.

Whilst beyond the scope of the current study, analogues that failed to produce a positive response in the NA release assay may have antagonist or weak partial agonist properties. If such compounds are identified and optimised, they may be expected to facilitate future studies to characterise the physiological and pathophysiological roles of this astrocytic signalling pathway.

The DiscoveRx panel screening is based on β-arrestin-induced internalisation and should be independent of the type of G-protein the receptor couples with. The approach is not very sensitive and, in the case of low-potency agonists such as LL, relatively high concentrations of agonist need to be employed, potentially leading to nonspecific effects. Only few concentration-dependent responses to LL (2–8 mM) were detected. When following up on the effect of LL on GPR162, we were unable to confirm a LL-induced change in cAMP production in transiently transfected HEK293 cells. This suggests that GPR162 does not signal via G_s-proteins and is therefore not consistent with LLRx function.

We acknowledge that we selected orphan candidates with medium to high expression levels in LC and with either unknown or proposed G_s-coupling in order to determine their cAMP response to LL (Table 4). Of these, only GPR137 produced a concentration-dependent but DL-insensitive increase in cAMP, making it an interesting candidate for further study. GPR137 has two paralogues, GPR137B and GPR137C, which are located on different chromosomes. Unusually for GPCRs, all three paralogues contain introns, raising the possibility of multiple variants through alternative splicing. GPR137 has been suggested to play a role in the proliferation of malignant tumours, but its functional significance for the brain has not yet been explored [52,53]. Neither ligands nor physiological actions of
GPR137B and GPR137C are currently established. However, as the cAMP response was not inhibited by co-application of DL, GPR137 does not fulfil all properties proposed for “LLRx” (Figure 4C).

Figure 4. L-lactate stimulates GPR137-dependent cAMP accumulation in HEK293 cells. (A) HEK293 cells transiently transfected with GPR137 (0.01 µg/µL) respond to 2 mM L-lactate (LL) with cAMP accumulation (GloSensor assay, n = 3, **p < 0.01 vs baseline (BL), one-way ANOVA with Tukey’s post-hoc test). (B) HEK293 cells expressing GPR137B do not respond to 2 mM LL. (C) Concentration range of LL and DL effects on cAMP in HEK293 cells transiently transfected with GPR137 (0.01 µg/µL). LL significantly increases cAMP at concentrations ≥ 1 mM. D-lactate (DL) elicits no response and does not significantly inhibit the effect of 2 mM LL (data are shown as mean ± SEM; n values for each dataset are represented in the respective columns; ****p < 0.0001, * p < 0.05 vs control, one-way ANOVA with Tukey’s post-hoc test).

Looking into the future, the list of potential LL receptor candidates is by no means complete if we include orphan GPCRs with low to medium expression levels such as GPR146 and others (not shown) to explore further as targets for LL-mediated signalling. Since LL-mediated release of NA is implicated in regulation of sleep/wake and attention states, learning and memory, and cardiorespiratory control, a better understanding of—and pharmacological tools to control—this signalling axis may have significant health implications.

Supplementary Materials: The following are available online at http://www.mdpi.com/2571-6980/1/2/25/s1, Figure S1. L-lactate evokes noradrenaline release from organotypic brain slices cultures as confirmed by using α1 CNiFER cells. Figure S2. L-lactate and analogues excite noradrenergic LC neurones.


Funding: This work was supported by grants from BBSRC BB/L019396/1, and MRC MR/L020661/1.

Acknowledgments: David Kleinfeld for his gift of CNiFER cells, Lesley Arberry for expert technical support, Andrew Herman for support with FACS sorting.

Conflicts of Interest: The authors declare no conflict of interest.
References


49. Cedarbaum, J.M.; Aghajanian, G.K. Activation of locus coeruleus neurons by peripheral stimuli: Modulation by a collateral inhibitory mechanism. Life Sci. 1978, 23, 1383–1392. [CrossRef]


© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).